
Robert Scott Carrico
Examiner (ID: 5184, Phone: (571)270-5504 , Office: P/1727 )
| Most Active Art Unit | 1727 |
| Art Unit(s) | 1727 |
| Total Applications | 729 |
| Issued Applications | 447 |
| Pending Applications | 79 |
| Abandoned Applications | 220 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19217843
[patent_doc_number] => 20240182547
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-06
[patent_title] => ANTI-RSV ANTIBODY AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
[patent_app_type] => utility
[patent_app_number] => 18/002881
[patent_app_country] => US
[patent_app_date] => 2021-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30393
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 748
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18002881
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/002881 | ANTI-RSV ANTIBODY AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | May 6, 2021 | Pending |
Array
(
[id] => 18466978
[patent_doc_number] => 20230201258
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => Polyspecific Binding Molecules and their use in Cell Therapy
[patent_app_type] => utility
[patent_app_number] => 17/996589
[patent_app_country] => US
[patent_app_date] => 2021-04-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26510
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17996589
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/996589 | Polyspecific Binding Molecules and their use in Cell Therapy | Apr 20, 2021 | Pending |
Array
(
[id] => 18451594
[patent_doc_number] => 20230192872
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => TOCILIZUMAB FOR THE TREATMENT OF VIRAL INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 17/995225
[patent_app_country] => US
[patent_app_date] => 2021-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12280
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17995225
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/995225 | TOCILIZUMAB FOR THE TREATMENT OF VIRAL INFECTIONS | Mar 31, 2021 | Abandoned |
Array
(
[id] => 18497431
[patent_doc_number] => 20230220066
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => CLAUDIN-6 TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/913899
[patent_app_country] => US
[patent_app_date] => 2021-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43121
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17913899
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/913899 | CLAUDIN-6 TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF | Mar 29, 2021 | Pending |
Array
(
[id] => 16868560
[patent_doc_number] => 20210162027
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => BOTULINUM NEUROTOXIN FOR TREATMENT OF DISORDERS ASSOCIATED WITH MELANOCYTE HYPERACTIVITY AND/OR EXCESS MELANIN
[patent_app_type] => utility
[patent_app_number] => 17/166386
[patent_app_country] => US
[patent_app_date] => 2021-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7330
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17166386
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/166386 | BOTULINUM NEUROTOXIN FOR TREATMENT OF DISORDERS ASSOCIATED WITH MELANOCYTE HYPERACTIVITY AND/OR EXCESS MELANIN | Feb 2, 2021 | Abandoned |
Array
(
[id] => 16837945
[patent_doc_number] => 20210145957
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/161119
[patent_app_country] => US
[patent_app_date] => 2021-01-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47444
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -39
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17161119
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/161119 | GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF | Jan 27, 2021 | Abandoned |
Array
(
[id] => 20402282
[patent_doc_number] => 12492251
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-09
[patent_title] => Human blood-brain barrier targeting antibodies
[patent_app_type] => utility
[patent_app_number] => 17/759854
[patent_app_country] => US
[patent_app_date] => 2021-01-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 10
[patent_no_of_words] => 18068
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 758
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17759854
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/759854 | Human blood-brain barrier targeting antibodies | Jan 27, 2021 | Issued |
Array
(
[id] => 18323400
[patent_doc_number] => 20230121528
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => SALMONELLA-BASED DNA VACCINES IN COMBINATION WITH AN ANTIBIOTIC
[patent_app_type] => utility
[patent_app_number] => 17/791282
[patent_app_country] => US
[patent_app_date] => 2021-01-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15363
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17791282
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/791282 | SALMONELLA-BASED DNA VACCINES IN COMBINATION WITH AN ANTIBIOTIC | Jan 11, 2021 | Abandoned |
Array
(
[id] => 19020189
[patent_doc_number] => 20240076360
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-07
[patent_title] => HUMANIZED ANTI-C5 ANTIBODIES AND FACTOR H FUSION PROTEINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/259106
[patent_app_country] => US
[patent_app_date] => 2020-12-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37676
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18259106
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/259106 | HUMANIZED ANTI-C5 ANTIBODIES AND FACTOR H FUSION PROTEINS AND USES THEREOF | Dec 24, 2020 | Pending |
Array
(
[id] => 18229955
[patent_doc_number] => 20230068949
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => New mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy
[patent_app_type] => utility
[patent_app_number] => 17/788133
[patent_app_country] => US
[patent_app_date] => 2020-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25258
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -47
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17788133
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/788133 | New mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy | Dec 21, 2020 | Pending |
Array
(
[id] => 16791726
[patent_doc_number] => 20210121543
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-29
[patent_title] => SUTURE LINE ADMINISTRATION TECHNIQUE USING BOTULINUM TOXINS
[patent_app_type] => utility
[patent_app_number] => 17/119880
[patent_app_country] => US
[patent_app_date] => 2020-12-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14693
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17119880
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/119880 | SUTURE LINE ADMINISTRATION TECHNIQUE USING BOTULINUM TOXINS | Dec 10, 2020 | Abandoned |
Array
(
[id] => 18451583
[patent_doc_number] => 20230192861
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => ANTI-PD-L1/ANTI-B7-H3 MULTISPECIFIC ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/778382
[patent_app_country] => US
[patent_app_date] => 2020-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27842
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17778382
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/778382 | ANTI-PD-L1/ANTI-B7-H3 MULTISPECIFIC ANTIBODIES AND USES THEREOF | Nov 22, 2020 | Pending |
Array
(
[id] => 19990919
[patent_doc_number] => 20250129141
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-24
[patent_title] => ANTIBODY FOR TETANUS TOXIN AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/033006
[patent_app_country] => US
[patent_app_date] => 2020-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5491
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18033006
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/033006 | Antibody for tetanus toxin and use thereof | Nov 18, 2020 | Issued |
Array
(
[id] => 16583210
[patent_doc_number] => 20210017612
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-21
[patent_title] => BACILLUS COMPOSITIONS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/034028
[patent_app_country] => US
[patent_app_date] => 2020-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11996
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17034028
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/034028 | BACILLUS COMPOSITIONS AND USES THEREOF | Sep 27, 2020 | Abandoned |
Array
(
[id] => 20644695
[patent_doc_number] => 12599620
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-04-14
[patent_title] => Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
[patent_app_type] => utility
[patent_app_number] => 17/638453
[patent_app_country] => US
[patent_app_date] => 2020-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2413
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17638453
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/638453 | Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells | Aug 30, 2020 | Issued |
Array
(
[id] => 16673134
[patent_doc_number] => 20210061897
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-04
[patent_title] => Antibodies to TGF-Beta
[patent_app_type] => utility
[patent_app_number] => 16/997365
[patent_app_country] => US
[patent_app_date] => 2020-08-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20636
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16997365
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/997365 | Antibodies to TGF-Beta | Aug 18, 2020 | Abandoned |
Array
(
[id] => 16582837
[patent_doc_number] => 20210017239
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-21
[patent_title] => PROTEINS WITH DIAGNOSTIC AND THERAPEUTIC USES
[patent_app_type] => utility
[patent_app_number] => 16/995344
[patent_app_country] => US
[patent_app_date] => 2020-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24236
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16995344
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/995344 | PROTEINS WITH DIAGNOSTIC AND THERAPEUTIC USES | Aug 16, 2020 | Abandoned |
Array
(
[id] => 17830163
[patent_doc_number] => 20220267467
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => POLYPEPTIDE COMPLEX FOR CONJUGATION AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/628008
[patent_app_country] => US
[patent_app_date] => 2020-07-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15820
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17628008
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/628008 | POLYPEPTIDE COMPLEX FOR CONJUGATION AND USE THEREOF | Jul 16, 2020 | Pending |
Array
(
[id] => 16581506
[patent_doc_number] => 20210015908
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-21
[patent_title] => METHODS FOR TREATING AND FOR INHIBITING PROGRESSION OF SEIZURES
[patent_app_type] => utility
[patent_app_number] => 16/921477
[patent_app_country] => US
[patent_app_date] => 2020-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10526
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16921477
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/921477 | METHODS FOR TREATING AND FOR INHIBITING PROGRESSION OF SEIZURES | Jul 5, 2020 | Abandoned |
Array
(
[id] => 20663675
[patent_doc_number] => 12605425
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-04-21
[patent_title] => TNF muteins and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/621711
[patent_app_country] => US
[patent_app_date] => 2020-06-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 24085
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17621711
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/621711 | TNF muteins and uses thereof | Jun 25, 2020 | Issued |